GeoVax Labs, Inc. will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on November 13, 2025. The clinical-stage biotechnology company will host a conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update. This announcement matters because GeoVax is developing critical medical solutions for vulnerable patient populations and advancing novel approaches to infectious disease prevention and cancer treatment.
The company's lead clinical program involves GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. These trials are evaluating the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers, who may not respond adequately to currently authorized COVID-19 vaccines. The vaccine is also being studied as a booster for patients with chronic lymphocytic leukemia and as a more robust, durable COVID-19 booster for healthy individuals who previously received mRNA vaccines. Access to the live conference call is available through registration at https://edge.media-server.com/mmc/p/u86rmdmb/.
In oncology, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance from the European Medicines Agency, anticipates progressing directly to Phase 3 clinical evaluation, bypassing earlier trial phases. The live audio webcast will be accessible through the company's investor relations website at https://www.geovax.com/investors.
The financial results and business update provide important insights into the progress of these clinical programs, which have significant implications for public health and medical treatment options. The development of effective vaccines for immunocompromised patients addresses a critical gap in current COVID-19 protection strategies, while the oncology and Mpox/smallpox programs represent potential advances in cancer treatment and infectious disease prevention. Investors and healthcare professionals will be monitoring these developments closely as they could influence future treatment protocols and vaccine availability.
An archive of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain accessible for at least 90 days. The outcomes of these clinical trials and the company's financial position could impact stock performance and future research funding, making this update significant for both the medical community and investment markets. For additional information about clinical trial status and company updates, visit https://www.geovax.com.
